Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 101–200 of 1,000
Austin, M., Yang, Y.-C., Vittinghoff, E., Adami, S., Boonen, S., Bauer, D. C., Bianchi, G., Bolognese, M. A., Christiansen, C., Eastell, R., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1472 · Cited by 182
Self-citationPathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B
Weenig, R. H. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.12.006 · Cited by 183
Qaseem, A., Snow, V., Shekelle, P., Hopkins, R., Forciea, M. A., Owens, D. K., & Clinical Efficacy Assessment Subcommittee of the American College of Physicians (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-6-200809160-00007 · Cited by 180
Cells of the synovium in rheumatoid arthritis. Osteoclasts.
Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2110 · Cited by 214
Jayatilaka, H., Tyle, P., Chen, J. J., Kwak, M., Ju, J., Kim, H. J., Lee, J. S. H., Wu, P.-H., Gilkes, D. M., Fan, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15584 · Cited by 177
The pathogenesis, diagnosis, investigation and management of osteoporosis
Sandhu, S. K., & Hampson, G. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.077842 · Cited by 172
RANKL/RANK control Brca1 mutation-driven mammary tumors
Sigl, V., Owusu-Boaitey, K., Joshi, P. A., Kavirayani, A., Wirnsberger, G., Novatchkova, M., Kozieradzki, I., Schramek, D., Edokobi, N., Hersl, J., et al. (2016) · Cell Research · doi:10.1038/cr.2016.69 · Cited by 175
Takeuchi, T., Tanaka, Y., Ishiguro, N., Yamanaka, H., Yoneda, T., Ohira, T., Okubo, N., Genant, H. K., & van der Heijde, D. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208052 · Cited by 168
Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials
Boquete‐Castro, A., Gómez‐Moreno, G., Calvo‐Guirado, J. L., Aguilar‐Salvatierra, A., & Delgado‐Ruiz, R. A. (2016) · Clinical Oral Implants Research · doi:10.1111/clr.12556 · Cited by 163
Davis, S., Simpson, E., Hamilton, J., James, M. M.-S., Rawdin, A., Wong, R., Goka, E., Gittoes, N., & Selby, P. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 164
Helas, S., Goettsch, C., Schoppet, M., Zeitz, U., Hempel, U., Morawietz, H., Kostenuik, P. J., Erben, R. G., & Hofbauer, L. C. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080957 · Cited by 159
Emerging therapeutic opportunities for skeletal restoration
Kawai, M., Mödder, U. I., Khosla, S., & Rosen, C. J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3299 · Cited by 159
Differing effects of denosumab and alendronate on cortical and trabecular bone
Zebaze, R. M., Libanati, C., Austin, M., Ghasem-Zadeh, A., Hanley, D. A., Zanchetta, J. R., Thomas, T., Boutroy, S., Bogado, C. E., Bilezikian, J. P., et al. (2014) · Bone · doi:10.1016/j.bone.2013.11.016 · Cited by 155
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari, S., & Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1326-y · Cited by 170
Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
Zhao, E., Wang, L., Dai, J., Kryczek, I., Wei, S., Vatan, L., Altuwaijri, S., Sparwasser, T. D., Wang, G., Keller, E. T., et al. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18480 · Cited by 170
Roux, C., Hofbauer, L. C., Ho, P. R., Wark, J. D., Zillikens, M. C., Fahrleitner-Pammer, A., Hawkins, F., Micaelo, M., Minisola, S., Papaioannou, N., et al. (2014) · Bone · doi:10.1016/j.bone.2013.10.006 · Cited by 158
Pathophysiology of hemophilic arthropathy and potential targets for therapy
Pulles, A. E., Mastbergen, S. C., Schutgens, R. E. G., Lafeber, F. P. J. G., & van Vulpen, L. F. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.11.032 · Cited by 168
McClung, M. R., Boonen, S., Törring, O., Roux, C., Rizzoli, R., Bone, H. G., Benhamou, C.-L., Lems, W. F., Minisola, S., Halse, J., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.536 · Cited by 154
Self-citationChen, X., Zhi, X., Wang, J., & Su, J. (2018) · Bone Research · doi:10.1038/s41413-018-0035-6 · Cited by 154
Lee, J., & Vasikaran, S. (2012) · Annals of Laboratory Medicine · doi:10.3343/alm.2012.32.2.105 · Cited by 146
Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Kranenburg, G., Bartstra, J. W., Weijmans, M., de Jong, P. A., Mali, W. P. T. M., Verhaar, H. J. J., Visseren, F. L. J., & Spiering, W. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.06.039 · Cited by 160
GERSTNER, G., DAMIANO, M. L., TOM, A., WORMAN, C., SCHULTZ, W., RECHT, M., & STOPECK, A. T. (2009) · Haemophilia · doi:10.1111/j.1365-2516.2008.01963.x · Cited by 148
Hanada, R., Hanada, T., Sigl, V., Schramek, D., & Penninger, J. M. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0749-z · Cited by 154
McCloskey, E. V., Johansson, H., Oden, A., Austin, M., Siris, E., Wang, A., Lewiecki, E. M., Lorenc, R., Libanati, C., & Kanis, J. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1606 · Cited by 142
Self-citationMiller, P. D., Wagman, R. B., Peacock, M., Lewiecki, E. M., Bolognese, M. A., Weinstein, R. L., Ding, B., Martín, J. S., & McClung, M. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1805 · Cited by 141
Self-citationItalian position paper ( SIPMO‐SICMF ) on medication‐related osteonecrosis of the jaw ( MRONJ )
Bedogni, A., Mauceri, R., Fusco, V., Bertoldo, F., Bettini, G., Fede, O. D., Casto, A. L., Marchetti, C., Panzarella, V., Saia, G., et al. (2024) · Oral Diseases · doi:10.1111/odi.14887 · Cited by 164
Henriksen, K., Tankó, L. B., Qvist, P., Delmas, P. D., Christiansen, C., & Karsdal, M. A. (2006) · Osteoporosis International · doi:10.1007/s00198-006-0286-8 · Cited by 145
Aguirre, J. I., Akhter, M. P., Kimmel, D. B., Pingel, J. E., Williams, A. A., Jorgensen, M., Kesavalu, L. N., & Wronski, T. J. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1669 · Cited by 141
Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases
Kikuta, J., & Ishii, M. (2012) · Rheumatology · doi:10.1093/rheumatology/kes259 · Cited by 150
Saag, K. G., Pannacciulli, N., Geusens, P., Adachi, J. D., Messina, O. D., Morales‐Torres, J., Emkey, R., Butler, P. W., Yin, X., & Lems, W. F. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40874 · Cited by 140
Clinical development of anti-RANKL therapy
Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 145
Karsdal, M. A., Henriksen, K., Leeming, D. J., Mitchell, P., Duffin, K., Barascuk, N., Klickstein, L., Aggarwal, P., Nemirovskiy, O., Byrjalsen, I., et al. (2009) · Biomarkers · doi:10.1080/13547500902777608 · Cited by 135
Jáuregui‐Lobera, I., Polo, I. M. L., González, M. T. M., & Millán, M. T. M. (2008) · Cited by 136
Watts, N. B., Roux, C., Modlin, J. F., Brown, J. P., Daniels, A., Jackson, S., Smith, S., Zack, D. J., Zhou, L., Grauer, A., et al. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1755-2 · Cited by 135
Ominsky, M. S., Li, X., Asuncion, F. J., Barrero, M., Warmington, K. S., Dwyer, D., Stolina, M., Geng, Z., Grisanti, M., Tan, H.-L., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080109 · Cited by 131
Prevention of glucocorticoid‐induced bone loss in mice by inhibition of RANKL
Hofbauer, L. C., Zeitz, U., Schoppet, M., Skalicky, M., Schüler, C., Stolina, M., Kostenuik, P. J., & Erben, R. G. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24445 · Cited by 132
The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
Castellano, D., Sepúlveda-Sánchez, J. M., García-Escobar, I., Rodríguez-Antolín, A., Sundlöv, A., & Cortés-Funes, H. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0154 · Cited by 138
Estrogens in rheumatoid arthritis; the immune system and bone
Islander, U., Jochéms, C., Lagerquist, M. K., Forsblad‐d’Elia, H., & Carlsten, H. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.05.018 · Cited by 148
Advances in osteoclast biology resulting from the study of osteopetrotic mutations
Segovia‐Silvestre, T., Neutzsky-Wulff, A. V., Sørensen, M. G., Christiansen, C., Bollerslev, J., Karsdal, M. A., & Henriksen, K. (2008) · Human Genetics · doi:10.1007/s00439-008-0583-8 · Cited by 139
Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
Hoyer‐Kuhn, H., Netzer, C., Koerber, F., Schöenau, E., & Semler, O. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0145-1 · Cited by 126
Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0056 · Cited by 131
Denosumab: Anti-RANKL antibody
Miller, P. D. (2009) · Current Osteoporosis Reports · doi:10.1007/s11914-009-0004-5 · Cited by 127
Self-citationImmunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases
Jennings, G. T., & Bachmann, M. F. (2008) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061008-103129 · Cited by 139
Adami, S., Libanati, C. R., Boonen, S., Cummings, S. R., Ho, P., Wang, A., Siris, E. S., Lane, J. M., Adachi, J. D., Bhandari, M., et al. (2012) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.k.00774 · Cited by 132
Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.
Hoyer‐Kuhn, H., Franklin, J., Allo, G., Kron, M. M., Netzer, C., Eysel, P., Hero, B., Schöenau, E., & Semler, O. (2016) · PubMed Central · Cited by 124
Drug induced osteonecrosis of the jaw
Hamadeh, I. S., Ngwa, B. A., & Gong, Y. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.04.007 · Cited by 173
Monoclonal gammopathy of undetermined significance: a consensus statement
Berenson, J. R., Anderson, K. C., Audell, R. A., Boccia, R. V., Coleman, M., Dimopoulos, M. A., Drake, M. T., Fonseca, R., Harousseau, J., Joshua, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08207.x · Cited by 134
Sutjandra, L., Rodriguez, R. D., Doshi, S., Ma, M., Peterson, M. C., Jang, G. R., Chow, A. T., & Ruixo, J. J. P. (2011) · Clinical Pharmacokinetics · doi:10.2165/11594240-000000000-00000 · Cited by 123
Self-citationLipton, A., Uzzo, R. G., Amato, R. J., Ellis, G. K., Hakimian, B., Roodman, G. D., & Smith, M. R. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0080 · Cited by 140
Review: Immune cells and mediators of inflammatory arthritis
Schett, G. A. (2008) · Autoimmunity · doi:10.1080/08916930701694717 · Cited by 134
Osteoporosis Associated with Neutralizing Autoantibodies against Osteoprotegerin
Riches, P. L., McRorie, E., Fraser, W. D., Determann, C., Hof, R. V., & Ralston, S. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810925 · Cited by 130
Idris, A. I., Landao‐Bassonga, E., & Ralston, S. H. (2010) · Bone · doi:10.1016/j.bone.2010.01.368 · Cited by 121
Physiological and Pharmacological Roles of PTH and PTHrP in Bone Using Their Shared Receptor, PTH1R
Martin, T. J., Sims, N. A., & Seeman, E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab005 · Cited by 129
Soluble Receptor Activator of Nuclear Factor-κB Ligand and Risk for Cardiovascular Disease
Kiechl, S., Schett, G., Schwaiger, J., Seppi, K., Eder, P., Egger, G., Santer, P., Mayr, A., Xu, Q., & Willeit, J. (2007) · Circulation · doi:10.1161/circulationaha.106.686774 · Cited by 117
Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 129
McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., & Miller, P. D. (2013) · Osteoporosis International · doi:10.1007/s00198-012-2052-4 · Cited by 115
Self-citationRoles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 122
Grey, A. B., Bolland, M. J., Horne, A. M., Wattie, D. J., House, M. E., Gamble, G. D., & Reid, I. R. (2012) · Bone · doi:10.1016/j.bone.2012.03.016 · Cited by 117
Karsdal, M. A., Woodworth, T., Henriksen, K., Maksymowych, W. P., Genant, H., Vergnaud, P., Christiansen, C., Schubert, T., Qvist, P., Schett, G., et al. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3280 · Cited by 114
Sfeir, J. G., Drake, M. T., Khosla, S., & Farr, J. N. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.03.011 · Cited by 105
Measurement of C-terminal telopeptide of type I collagen (CTX) in serum
Chubb, S. A. P. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.035 · Cited by 124
Metabolic bone disease in HIV infection
Borderi, M., Gibellini, D., Vescini, F., Crignis, E. D., Cimatti, L., Biagetti, C., Tampellini, L., & Re, M. C. (2009) · AIDS · doi:10.1097/qad.0b013e32832ce85a · Cited by 124
Lyu, H., Jundi, B., Xu, C. Q., Tedeschi, S. K., Yoshida, K., Zhao, S. S., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02236 · Cited by 118
Lamy, O., Stoll, D., Aubry‐Rozier, B., & Rodríguez, E. G. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00502-4 · Cited by 110
Molecular mechanisms of inflammatory bone damage: emerging targets for therapy
Herman, S., Krönke, G., & Schett, G. A. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.04.001 · Cited by 122
First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI.
Semler, O., Netzer, C., Hoyer‐Kuhn, H., Becker, J., Eysel, P., & Schöenau, E. (2012) · PubMed · Cited by 107
Aortic valve calcification: basic science to clinical practice
Akat, K., Borggrefe, M., & Kaden, J. J. (2009) · Heart · doi:10.1136/hrt.2007.134783 · Cited by 103
Body, J. J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1223-4 · Cited by 116
Danks, L., & Takayanagi, H. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt049 · Cited by 119
Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
on behalf of the DAPS Investigators, Kendler, D. L., McClung, M. R., Freemantle, N., Lillestol, M. J., Moffett, A. H., Borenstein, J. E., Satram‐Hoang, S., Yang, Y., Kaur, P. P., et al. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1378-z · Cited by 111
Self-citationSchlieper, G., Westenfeld, R., Brandenburg, V. M., & Ketteler, M. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00257.x · Cited by 110
Anastasilakis, A. D., Toulis, K. A., Goulis, D. G., Pοlyzos, S. A., Delaroudis, S., Giomisi, A., & Terpos, E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1224109 · Cited by 109
Saylor, P. J., & Smith, M. R. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0014 · Cited by 107
Tak, P. P., Balanescu, A. R., Tseluyko, V., Bojin, S., Drescher, E., Dairaghi, D. J., Miao, S., Marchesin, V., Jaén, J. C., Schall, T. J., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-201605 · Cited by 100
Self-citationUpdate in Osteoporosis and Metabolic Bone Disorders
Shoback, D. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0042 · Cited by 113
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver
Musso, G., Paschetta, E., Gambino, R., Cassader, M., & Molinaro, F. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.006 · Cited by 102
RANKL, denosumab, and giant cell tumor of bone
Thomas, D. M. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354c129 · Cited by 104
Dempster, D. W., Brown, J. P., Fahrleitner‐Pammer, A., Kendler, D. L., Rizzo, S., Valter, I., Wagman, R. B., Yin, X., Yue, S. V., & Boivin, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02669 · Cited by 97
Bisphosphonates and osteonecrosis of the jaws: Science and rationale
Gutta, R., & Louis, P. J. S. (2007) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.12.004 · Cited by 97
Seibel, M. J. (2006) · PubMed · Cited by 126
Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series
Müller, D. A., Beltrami, G., Scoccianti, G., Campanacci, D. A., Franchi, A., & Capanna, R. (2016) · World Journal of Surgical Oncology · doi:10.1186/s12957-016-1034-y · Cited by 96
Lumachi, F., Brunello, A., Roma, A., & Basso, U. (2009) · PubMed · Cited by 96
Role of RANKL inhibition in osteoporosis
McClung, M. R. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2167 · Cited by 112
Self-citationScreening, diagnosis and treatment of osteoporosis: a brief review
Bernabei, R., Martone, A. M., Ortolani, E., Landi, F., & Marzetti, E. (2014) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2014.11.3.201 · Cited by 127
Hadji, P., Παπαϊωάννου, Ν., Gielen, E., Tepie, M. F., Zhang, E., Frieling, I., Geusens, P., Makras, P., Resch, H., Möller, G., et al. (2015) · Osteoporosis International · doi:10.1007/s00198-015-3164-4 · Cited by 93
Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
Anastasilakis, A. D., Toulis, K. A., Πολύζος, Σ., Anastasilakis, C. D., & Makras, P. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s24239 · Cited by 98
Evaluating distant metastases in breast cancer: from biology to outcomes
Rabbani, S. A., & Mazar, A. P. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9085-8 · Cited by 104
Human Monoclonal Antibodies from Transgenic Mice
Lonberg, N. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 85
Anti-resorptive therapies for osteoporosis
Reid, I. R. (2008) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2008.08.002 · Cited by 95
RANKL blockade prevents and treats aggressive osteosarcomas
Chen, Y., Di Grappa, M. A., Molyneux, S. D., McKee, T. D., Waterhouse, P., Penninger, J. M., & Khokha, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad0295 · Cited by 88
The underlying pathophysiology and therapeutic approaches for osteoporosis
Awasthi, H., Mani, D., Singh, D. R., & Gupta, A. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21504 · Cited by 91
Bisphosphonate treatment: An orthodontic concern calling for a proactive approach
Zahrowski, J. J. (2007) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2006.09.035 · Cited by 90
Daponte, V., Henke, K., & Drissi, H. (2024) · eLife · doi:10.7554/elife.95083 · Cited by 96
Genant, H. K., Engelke, K., Hanley, D. A., Brown, J. P., Omizo, M., Bone, H. G., Kivitz, A., Fuerst, T. P., Wang, H., Austin, M., et al. (2010) · Bone · doi:10.1016/j.bone.2010.04.594 · Cited by 93
Self-citationOsteoclasts and the immune system
Nakashima, T., & Takayanagi, H. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0089-z · Cited by 94
Cremers, S., & Garnero, P. (2006) · Drugs · doi:10.2165/00003495-200666160-00001 · Cited by 95
Murai, I. H., Roschel, H., Dantas, W. S., Gil, S., Merege-Filho, C., de Cleva, R., de Sá-Pinto, A. L., Lima, F., Santo, M. A., Benatti, F. B., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00074 · Cited by 83
Meguid, M. H. A., Hammad, Y. H., Swilam, R. S., & Barakat, M. S. (2012) · Rheumatology International · doi:10.1007/s00296-012-2375-7 · Cited by 94
Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis
Ramchand, S. K., & Leder, B. Z. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad496 · Cited by 86
Hines, S. L., Mincey, B. A., Sloan, J. A., Thomas, S. P., Chottiner, E. G., Loprinzi, C. L., Carlson, M. D., Atherton, P. J., Salim, M., & Perez, E. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1783 · Cited by 86
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.